ArticleOncogene2017
microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-β actions.
Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Crosstalk between KRAS and miRNAs in pancreatic cancer: Opportunities for its diagnosis, prognosis and therapeutic intervention (Review).International journal of oncology · 2026Review
- Allicin: a promising modulator of apoptosis and survival signaling in cancer.Medical oncology (Northwood, London, England) · 2024Review
- circEIF3I facilitates the recruitment of SMAD3 to early endosomes to promote TGF-β signalling pathway-mediated activation of MMPs in pancreatic cancer.Molecular cancer · 2023Article
- The Role of Krüppel-like Factors in Pancreatic Physiology and Pathophysiology.International journal of molecular sciences · 2023Review
- Article
- TGFβ Signaling in the Pancreatic Tumor Microenvironment.Cancers · 2021Review
- Suppression of miR-106a-5p expression inhibits tumorigenesis via increasing CELF-2 expression in spinal cord glioma.Oncology letters · 2021Article
- miR-3613-5p enhances the metastasis of pancreatic cancer by targeting CDK6.Cell cycle (Georgetown, Tex.) · 2020Article
- MicroRNA-1469-5p promotes the invasion and proliferation of pancreatic cancer cells via direct regulating the NDRG1/NF-κB/E-cadherin axis.Human cell · 2020Article
- miR‑539 suppresses the proliferation, migration, invasion and epithelial mesenchymal transition of pancreatic cancer cells through targeting SP1.International journal of molecular medicine · 2020Article
- Elevated expression of exosomal microRNA-21 as a potential biomarker for the early diagnosis of pancreatic cancer using a tethered cationic lipoplex nanoparticle biochip.Oncology letters · 2020Article
- Effect and mechanism of microRNA-10b on proliferation and invasion of esophageal cancer cells.Experimental and therapeutic medicine · 2019Article
- Down-regulation of miR-489 contributes into NSCLC cell invasion through targeting SUZ12.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- MiR-9 and miR-21 as prognostic biomarkers for recurrence in papillary thyroid cancer.Clinical & experimental metastasis · 2015Article
- MicroRNA-10b indicates a poor prognosis of non-small cell lung cancer and targets E-cadherin.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2015Article
- Involvement of epithelial to mesenchymal transition in the development of pancreatic ductal adenocarcinoma.Journal of gastroenterology · 2015Review
- Article
- Up-regulation of microRNA-10b is associated with the development of breast cancer brain metastasis.American journal of translational research · 2014Article
Corrections and comments
- Erratum for
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This corrects the article DOI: 10.1038/onc.2013.405.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.